SCM
ALT icon

Silverarc Capital Management’s Altimmune ALT Stock Holding History

Silverarc Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-415,700
Closed -$1.75M – 85
2023
Q1 		$1.75M Buy
415,700
+255,700
+160% +$3.04M 0.72% 47
2022
Q4 		$2.63M Buy
+160,000
New +$1.8M 0.75% 46

Other funds holding ALT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Silverarc Capital Management's ALT Position: Q1 2024 in Review

Silverarc Capital Management sold out of Altimmune (ALT) in Q1 2024, closing a stake of 150,000 shares — an estimated $1.69M sold.

Silverarc Capital Management first reported a position in ALT in Q3 2022 and held it in 3 quarters. The position peaked at $1.69M in Q4 2023. 172 funds tracked by Wall St. Rank hold ALT as of Q1 2024.

  • Silverarc Capital Management reported no remaining Altimmune position as of Q1 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 150,000 Altimmune shares in Q1 2024, an estimated $1.69M.
  • Silverarc Capital Management first reported a position in Altimmune in Q3 2022 and held it in 3 quarters.
  • Silverarc Capital Management's Altimmune position peaked at $1.69M in Q4 2023.
  • 172 funds tracked by Wall St. Rank held Altimmune as of Q1 2024.

Based on Silverarc Capital Management's 13F filing for Q1 2024, filed 15 May 2024.